The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data. Issue 4 (25th June 2019)

• Record Type: Journal Article
• Authors: Salman, Andac; Demir, Gizem; Bekiroglu, Nural
• Is Part Of: Dermatologic therapy. Volume 32:Issue 4(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-06-25
• Subjects: chronic spontaneous urticaria -- omalizumab -- quality of life -- real‐life -- treatment -- urticaria; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.12975
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Background: Omalizumab is a third‐line treatment for chronic spontaneous urticaria (CSU). However, the real‐life data on the impact of omalizumab on CSU‐related quality of life (QoL) remain scarce. Objectives: To investigate the impact of omalizumab on QoL and its predictors in CSU. A retrospective cohort study was done. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT); the impairment in QoL was assessed using dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU‐Q2oL). Results: Forty‐two patients were included. All scores improved from baseline to first month and remained stable at the third month of treatment ( p < .001). The gender, age, and angioedema had no significant effect on QoL, but the complete responders (UAS7:0–1) had better improvement rates in all scores compared to others. The baseline UAS7, DLQI, and CU‐Q2oL scores were lower at the baseline in complete responders ( p = .0001). Conclusions: A rapid and continual improvement in QoL was obtained with omalizumab treatment. A better UAS7, UCT, DLQI, and CU‐Q2oL score at the baseline might be a predictor of a better response to omalizumab and more improvement in QoL.